MannKind Company Profile (NASDAQ:MNKD)

About MannKind

MannKind logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MNKD
  • CUSIP: 56400P20
Key Metrics:
  • Previous Close: $0.51
  • 50 Day Moving Average: $0.6018
  • 200 Day Moving Average: $0.6416
  • 52-Week Range: $478,376,000.00 - $0.41
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.86
  • P/E Growth: 0.1600
  • Market Cap: $245.93M
  • Outstanding Shares: 478,376,000
  • Beta: 3.26
Profitability:
  • Return on Equity: -15.95%
  • Return on Assets: 46.57%
Debt:
  • Debt-to-Equity Ratio: -0.62%
  • Current Ratio: 0.46%
  • Quick Ratio: 0.41%
Additional Links:
Companies Related to MannKind:

Analyst Ratings

Consensus Ratings for MannKind (NASDAQ:MNKD) (?)
Ratings Breakdown: 4 Sell Ratings, 1 Hold Rating
Consensus Rating:Sell (Score: 1.20)
Consensus Price Target: $0.32 (38.40% downside)

Analysts' Ratings History for MannKind (NASDAQ:MNKD)
Show:
DateFirmActionRatingPrice TargetDetails
11/11/2016J P Morgan Chase & CoReiterated RatingUnderweightView Rating Details
8/31/2016S&P Equity ResearchLower Price Target$0.84 -> $0.70View Rating Details
8/21/2016Piper Jaffray CompaniesSet Price TargetSell$0.10View Rating Details
6/1/2016Royal Bank of CanadaLower Price TargetUnderperform$1.00 -> $0.15View Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldView Rating Details
4/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingSellView Rating Details
1/6/2016Griffin SecuritiesUpgradeNeutral -> Buy$4.00View Rating Details
11/14/2015Jefferies Group LLCReiterated RatingBuy$9.00View Rating Details
5/11/2015MLV & Co.Lower Price TargetHold$7.00 -> $4.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for MannKind (NASDAQ:MNKD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/9/2016Q3 2016($0.05)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)ViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.04($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.12)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MannKind (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $0.1200 EPS
Next Year EPS Consensus Estimate: $-0.1800 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.03)($0.03)($0.03)
Q2 20161($0.03)($0.03)($0.03)
Q3 20161($0.03)($0.03)($0.03)
Q4 20161($0.03)($0.03)($0.03)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MannKind (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MannKind (NASDAQ:MNKD)
Insider Ownership Percentage: 0.94%
Institutional Ownership Percentage: 19.71%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.00View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.00View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.00View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.12View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for MannKind (NASDAQ:MNKD)
DateHeadline
News IconAnalysts Are Circling MannKind Corporation (NASDAQ:MNKD): Where Do Research Brokers See It Going? - Winfield Review (NASDAQ:MNKD)
winfieldreview.com - February 26 at 7:26 AM
News IconVANGUARD GROUP INC is the biggest holder of MannKind ... - Post Analyst (NASDAQ:MNKD)
postanalyst.com - February 26 at 7:26 AM
openpr.com logoGrowing Awareness among Consumers and Increasing Disposable Income are Projected to Drive Global Pulmonary Drug Delivery Systems (NASDAQ:MNKD)
www.openpr.com - February 24 at 9:23 AM
News IconMannKind Corporation (NASDAQ:MNKD) Consensus Alert - Aiken Advocate (NASDAQ:MNKD)
aikenadvocate.com - February 23 at 11:40 PM
News IconWatching the Levels for MannKind Corporation (NASDAQ:MNKD) - BVN (NASDAQ:MNKD)
bvnewsjournal.com - February 23 at 11:40 PM
biz.yahoo.com logoMANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets (NASDAQ:MNKD)
biz.yahoo.com - February 23 at 6:40 PM
News IconMannKind Corporation (NASDAQ:MNKD) Improves Cash Position As It Works To Grow Afrezza Sales - Traders350 (NASDAQ:MNKD)
traders350.com - February 23 at 8:00 AM
News IconResearch Report for: Boston Scientific Corporation (NYSE:BSX) (NASDAQ:MNKD)
oakridgeobserver.com - February 22 at 11:46 PM
nasdaq.com logoNotable Wednesday Option Activity: AAWW, MNKD, TREX (NASDAQ:MNKD)
www.nasdaq.com - February 22 at 6:44 PM
News IconAnalysts Near-Term outlook: Hornbeck Offshore Services, Inc. (HOS), MannKind Corporation (MNKD) - The USA Commerce (NASDAQ:MNKD)
www.theusacommerce.com - February 22 at 8:25 AM
News IconHow Does MannKind Corporation (MNKD) Stack Up Right Now? - StockNewsJournal (NASDAQ:MNKD)
stocknewsjournal.com - February 22 at 8:25 AM
finance.yahoo.com logoMannKind Receives $16.7 Million From Sale of Valencia Property (NASDAQ:MNKD)
finance.yahoo.com - February 21 at 6:21 PM
finance.yahoo.com logo9:03 am Mannkind receives $16.7 mln upon closing the sale of real estate owned by the co in Valencia, California, net of closing costs (NASDAQ:MNKD)
finance.yahoo.com - February 21 at 6:21 PM
seekingalpha.com logoMannKind - Afrezza Sales Slip As New Sales Force Starts - Seeking Alpha (NASDAQ:MNKD)
seekingalpha.com - February 19 at 5:40 PM
News IconMannKind Corporation (NASDAQ:MNKD) Stock Alert: Price Target in Focus - Aiken Advocate (NASDAQ:MNKD)
aikenadvocate.com - February 19 at 5:40 PM
News IconAnalysts Are Sizing Up MannKind Corporation (NASDAQ:MNKD): Where Does the Sell-Side See It Going? - Winfield Review (NASDAQ:MNKD)
winfieldreview.com - February 19 at 5:40 PM
News IconAnalyst Issued Price Target in Spotlight for MannKind Corporation (NASDAQ:MNKD) - Aiken Advocate (NASDAQ:MNKD)
aikenadvocate.com - February 18 at 5:48 PM
News IconAnalysts Place Consensus Target on MannKind Corporation (NASDAQ:MNKD) at 0.15 - Aiken Advocate (NASDAQ:MNKD)
aikenadvocate.com - February 17 at 3:34 PM
seekingalpha.com logoMannKind, Afrezza Sales, And 'Free Beer Tomorrow' - Seeking Alpha (NASDAQ:MNKD)
seekingalpha.com - February 11 at 6:42 PM
einnews.com logoMannKind Corp Consumption, Competitor and Forecast 2017 – 2022 (NASDAQ:MNKD)
www.einnews.com - February 10 at 7:28 PM
News IconMannKind takes steps to boost stock, Afrezza sales (NASDAQ:MNKD)
signalscv.com - February 8 at 1:01 AM
fool.com logoHere's Why MannKind Corporation Rose 11.5% in January - Motley Fool (NASDAQ:MNKD)
www.fool.com - February 7 at 7:38 AM
fool.com logoHere's Why MannKind Corporation Rose 11.5% in January (NASDAQ:MNKD)
www.fool.com - February 6 at 10:11 AM
News IconStock Price of MannKind Corporation (MNKD) Decreases -15.52% - Highland Mirror (NASDAQ:MNKD)
www.highlandmirror.com - February 6 at 9:50 AM
News IconMannKind Corp MNKD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MNKD)
www.bioportfolio.com - February 5 at 6:23 PM
News IconBiotech Stocks Under Scanner -- Mast Therapeutics, MannKind, Celgene, and Opko Health (NASDAQ:MNKD)
www.bio-medicine.org - February 3 at 7:18 PM
seekingalpha.com logoMannKind: The Saga Of Smoking Guns (NASDAQ:MNKD)
seekingalpha.com - February 3 at 7:18 PM
streetinsider.com logoForm 5 MANNKIND CORP For: Dec 31 Filed by: KRESA KENT (NASDAQ:MNKD)
www.streetinsider.com - February 3 at 5:28 AM
4-traders.com logoMannKind : Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth (NASDAQ:MNKD)
www.4-traders.com - February 2 at 7:25 PM
News IconMannKind Proposes Reverse Stock Split (NASDAQ:MNKD)
sfvbj.com - February 2 at 7:25 PM
News IconMannKind (MNKD) Stock: Taking A Dive On Reverse Split (NASDAQ:MNKD)
cnafinance.com - February 2 at 7:25 PM
News IconHere's Why MannKind Corporation Is Plunging (NASDAQ:MNKD)
www.foxbusiness.com - February 2 at 7:25 PM
fool.com logoGood News and Bad News for MannKind Corporation (NASDAQ:MNKD)
www.fool.com - February 2 at 7:25 PM
thestreet.com logoMannkind in Free Fall After Changes to Insulin Product, Sales Force (NASDAQ:MNKD)
www.thestreet.com - February 2 at 7:25 PM
fool.com logoHere's Why MannKind Corporation Is Plunging (NASDAQ:MNKD)
www.fool.com - February 2 at 7:25 PM
investopedia.com logoMannKind Looks to Boost Flagging Afrezza Sales (NASDAQ:MNKD)
www.investopedia.com - February 2 at 7:25 PM
seekingalpha.com logoMannKind refines commercial approach for Afrezza; reverse stock split proposed; shares down 16% (NASDAQ:MNKD)
seekingalpha.com - February 2 at 1:19 PM
streetinsider.com logoMannKind (MNKD) Launches Titration Pack; Transitioning Sales Force from Contract to Expanded Team Staffed by MannKind Employees (NASDAQ:MNKD)
www.streetinsider.com - February 2 at 5:31 AM
News IconMannKind moves to accelerate Afrezza growth (NASDAQ:MNKD)
www.thepharmaletter.com - February 1 at 7:31 PM
streetinsider.com logoMannKind (MNKD) Investors to Vote on Reverse Stock Split at Special Meeting in February (NASDAQ:MNKD)
www.streetinsider.com - February 1 at 7:31 PM
smarteranalyst.com logoStock Update (NASDAQ:MNKD): MannKind Corporation Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth (NASDAQ:MNKD)
www.smarteranalyst.com - February 1 at 7:31 PM
us.rd.yahoo.com logoMannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza® Growth (NASDAQ:MNKD)
us.rd.yahoo.com - February 1 at 7:31 PM
News IconStocks Alert: Horizon Global Corporation (NYSE:HZN), MannKind Corp. (NASDAQ:MNKD) - The Newburgh Press (NASDAQ:MNKD)
newburghpress.com - January 31 at 12:21 AM
News IconJust the Facts on MannKind Corporation (MNKD) - StockNewsJournal (NASDAQ:MNKD)
stocknewsjournal.com - January 31 at 12:21 AM
News IconFCF Score Check on Shares of MannKind Corporation (NASDAQ:MNKD) - The Tribune (NASDAQ:MNKD)
lakecitytribune.com - January 28 at 6:42 PM
News IconInvestor's Watch List: MannKind Corporation (NASDAQ:MNKD), 3D Systems Corporation (NYSE:DDD) - The Newburgh Press (NASDAQ:MNKD)
newburghpress.com - January 28 at 1:46 AM
News IconIs There Inherent Value in MannKind Corporation (NASDAQ:MNKD)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:MNKD)
wsbeacon.com - January 28 at 1:46 AM
finance.yahoo.com logoMannKind Corporation to Hold Investor Conference Call on February 1, 2017 (NASDAQ:MNKD)
finance.yahoo.com - January 28 at 1:46 AM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on MannKind Corporation (NASDAQ:MNKD) - Wall Street Beacon (NASDAQ:MNKD)
wsbeacon.com - January 26 at 9:47 PM
News IconEarnings in Full Force, Analysts Take Aim at MannKind Corporation (NASDAQ:MNKD) - Wall Street Beacon (NASDAQ:MNKD)
wsbeacon.com - January 26 at 9:47 PM

Social

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Where is MannKind's stock going? Where will MannKind's stock price be in 2017?

5 brokers have issued 12 month price objectives for MannKind's shares. Their predictions range from $0.10 to $0.70. On average, they expect MannKind's share price to reach $0.32 in the next year.

When will MannKind announce their earnings?

MannKind is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns MannKind stock?

MannKind's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.06%), Harel Insurance Investments & Financial Services Ltd. (0.62%), GSA Capital Partners LLP (0.52%) and State Board of Administration of Florida Retirement System (0.03%). Company insiders that own MannKind stock include Hakan Edstrom, Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya.

Who bought MannKind stock? Who is buying MannKind stock?

MannKind's stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and State Street Corp. Company insiders that have bought MannKind stock in the last two years include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya.

How do I buy MannKind stock?

Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of MannKind stock cost?

One share of MannKind stock can currently be purchased for approximately $0.51.

MannKind (NASDAQ:MNKD) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

Earnings History Chart

Earnings by Quarter for MannKind (NASDAQ:MNKD)

Dividend History Chart

Dividend Payments by Quarter for MannKind (NASDAQ:MNKD)

Last Updated on 2/27/2017 by MarketBeat.com Staff